Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Top Gainers & Losers on Mar 12: Piramal Pharma, Tejas Networks, Apollo Tyres, PG Electroplast among top losers
The Indian stock market extended its losses on March 12, with the Nifty 50 and Sensex down 1% and 1.08%. Tensions in the Middle East affected investor sentiment, particularly impacting auto stocks, while broader markets showed some positive movement.
PE Firm True North Sells 3.6% Stake In Anthem Biosciences For Rs 1,261 Crore
HDFC Mutual Fund (MF) and SBI MF have collectively acquired 93,01,020 shares or 1.65% holding in Anthem Biosciences at an average price of Rs 621.10 apiece.
Market Trading Guide: Apollo Pipes among 3 stock recommendations for Tuesday
Sensex and Nifty plunged nearly 2% as rising crude oil prices, weak global cues and escalating West Asia tensions triggered heavy selling. Foreign fund outflows and a weaker rupee added pressure. Analysts recommend Apollo Pipes, Aurobindo Pharma and Tata Steel for potential short-term gains.
Top Gainers & Losers on Feb 26: Tejas Networks, KSB, Mankind Pharma, Tata Motors, Finolex Cables among top gainers
The Indian stock market remained largely unchanged on February 26, with the Nifty 50 up 0.06% at 25,496 and the S&P BSE Sensex flat at 82,248. Broader markets showed mixed results, while US stocks rallied on Nvidia's strong earnings, boosting Asian markets as well.
Sebi sends show-cause notice to ZEEL over 'fund diversion'
India's market regulator Sebi has issued a show cause notice to Zee Entertainment Enterprises and its top executives. The notice alleges fund diversion and governance lapses. Zee Entertainment has denied all allegations. The company plans to file a response and take legal steps to protect shareholder interests.
Sebi sends show-cause notice to ZEEL over 'fund diversion'
India's market regulator Sebi has issued a show cause notice to Zee Entertainment Enterprises and its top executives. The notice alleges fund diversion and governance lapses. Zee Entertainment has denied all allegations. The company plans to file a response and take legal steps to protect shareholder interests.
SBI MF, Nippon India MF buy Rs 272 crore worth Pine Labs shares; ICICI Pru MF acquire 1.5% stake in Indoco Remedies
SBI Mutual Fund through SBI Midcap Fund held 5.24 percent stake in Pine Labs, the point of sale and payment systems provider, as of March 2026.
Taking Stock: Markets rebound; Nifty reclaims 24,150, Sensex jumps 600 pts
Among the top gainers on the index were Maruti Suzuki India, Coal India, Tech Mahindra, ITC Limited, and Reliance Industries. On the downside, InterGlobe Aviation, Dr. Reddy's Laboratories, NTPC, ICICI Bank and Bajaj Finserv were among the key laggards.
Nifty recovers 200 points from intra-day lows; IT continues outperformance | Closing Bell
Indian equities erased all the intraday losses with Nifty back above 23,500. TCS, Infosys, HCL Tech, Tech Mahindra, Trent are among top gainers on the Nifty, while losers are NTPC, Power Grid Corp, Cipla, Dr Reddy's Labs and L&T. Among sectors IT index up 4%, while auto, metal, Consumer Durables, realty up 0.5% each. However, pharma, healthcare, power, media, energy down 0.5-1%. Nifty Midcap and Smallcap indices down marginally. Catch Lovish Darad in conversation with Market Experts.
Cipla stock up 4% to emerge as top Nifty gainer; Citi sees series of near-term positive US triggers
The stock was trading at Rs 1,407, up 4.08 percent.
Dr Reddy’s stock up over 1%, among top Nifty gainers today; Nomura bullish on branded drugs push; check upside
The brokerage said Dr Reddy's strategic focus is increasingly shifting towards branded generics and consumer healthcare businesses, with recent acquisitions largely aimed at strengthening its branded portfolio.
Nifty Pharma jumps nearly 2%; Dr Reddy's, Sun Pharma and Cipla lead gains, dominate Nifty gainers list
Pharma stocks led the gains on benchmark Nifty 50 and the BSE Midcap index on Tuesday. Dr Reddy's, Sun Pharma and Cipla were the top 3 Nifty gainers, amid news reports that the US FDA has asked Indian firms to help address a shortage of ifosfamide injection.